Evidence map›Paper›PMID 25271301›Full record

ArticleMolecular & cellular proteomics : MCP2014

Integrated omic analysis of oropharyngeal carcinomas reveals human papillomavirus (HPV)-dependent regulation of the activator protein 1 (AP-1) pathway.

Lusia Sepiashvili, Daryl Waggott, Angela Hui, Wei Shi, Susie Su, Alex Ignatchenko, Vladimir Ignatchenko, Marissa Laureano, Shao Hui Huang, Wei Xu and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Lusia SepiashviliFrom the ‡Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M5G 1L7; §Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada M5T 2M9;
Daryl Waggott¶Informatics & Biocomputing, Ontario Institute for Cancer Research, Toronto, Ontario, Canada M5G 0A3;
Angela Hui§Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada M5T 2M9;
Wei Shi§Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada M5T 2M9;
Susie Su‖Division of Biostatistics, University of Toronto, Toronto, Ontario, Canada M5G 2M9;
Alex Ignatchenko§Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada M5T 2M9;
Vladimir Ignatchenko§Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada M5T 2M9;
Marissa Laureano§Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada M5T 2M9;
Shao Hui Huang**Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada M5G 2M9;
Wei Xu‖Division of Biostatistics, University of Toronto, Toronto, Ontario, Canada M5G 2M9;
Ilan Weinreb‡‡Department of Pathology, University of Toronto, Toronto, Ontario, Canada M5G 2C4;
John Waldron**Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada M5G 2M9;
Brian O'Sullivan**Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada M5G 2M9;
Jonathan C Irish§§Department of Surgery, University of Toronto, Toronto, Ontario, Canada M5G 2M9;
Paul C BoutrosFrom the ‡Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M5G 1L7; ¶Informatics & Biocomputing, Ontario Institute for Cancer Research, Toronto, Ontario, Canada M5G 0A3; ¶¶Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada M5G 0A3.
Fei-Fei LiuFrom the ‡Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M5G 1L7; §Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada M5T 2M9; **Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada M5G 2M9; thomas.kislinger@utoronto.ca Fei-Fei.Liu@rmp.uhn.on.ca.
Thomas KislingerFrom the ‡Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M5G 1L7; §Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada M5T 2M9; thomas.kislinger@utoronto.ca Fei-Fei.Liu@rmp.uhn.on.ca.
University of Toronto · CAPrincess Margaret Cancer Centre · CAOntario Institute for Cancer Research · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

HPV-positive oropharyngeal carcinoma (OPC) patients have superior outcomes relative to HPV-negative patients, but the underlying mechanisms remain poorly understood. We conducted a proteomic investigation of HPV-positive (n = 27) and HPV-negative (n = 26) formalin-fixed paraffin-embedded OPC biopsies to acquire insights into the biological pathways that correlate with clinical behavior. Among the 2,633 proteins identified, 174 were differentially abundant. These were enriched for proteins related to cell cycle, DNA replication, apoptosis, and immune response. The differential abundances of cortactin and methylthioadenosine phosphorylase were validated by immunohistochemistry in an independent cohort of 29 OPC samples (p = 0.023 and p = 0.009, respectively). An additional 1,124 proteins were independently corroborated through comparison to a published proteomic dataset of OPC. Furthermore, utilizing the Cancer Genome Atlas, we conducted an integrated investigation of OPC, attributing mechanisms underlying differential protein abundances to alterations in mutation, copy number, methylation, and mRNA profiles. A key finding of this integration was the identification of elevated cortactin oncoprotein levels in HPV-negative OPCs. These proteins might contribute to reduced survival in these patients via their established role in radiation resistance. Through interrogation of Cancer Genome Atlas data, we demonstrated that activation of the β1-integrin/FAK/cortactin/JNK1 signaling axis and associated differential regulation of activator protein 1 transcription factor target genes are plausible consequences of elevated cortactin protein levels.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedAged, 80 and overApoptosisCarcinomaCell CycleCohort StudiesCortactinDNA ReplicationFemaleFocal Adhesion Kinase 1Host-Pathogen InteractionsHumansImmunity, InnateIntegrin beta15'-methylthioadenosine phosphorylaseCortactinCTTN protein, humanFocal Adhesion Kinase 1Integrin beta1Mitogen-Activated Protein Kinase 8PTK2 protein, humanPurine-Nucleoside PhosphorylaseTranscription Factor AP-1

Identifiers

PMID25271301
PMCPMC4256506
OpenAlexW2061678926

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.